CMS May Review Rx Prices In Medicare Bids; “Non-Interference” Has Limits
The Medicare Part D implementing regs would allow CMS to ask drug plan sponsors to provide detailed descriptions of manufacturer-level prices and rebates in cases where bids appear "unusually" high or low
You may also be interested in...
Potential Medicare prescription drug insurance plan providers should consider the "donut hole" to be a form of reinsurance that limits their exposure to risk, the Centers for Medicare & Medicaid Services suggests
Consumers will "flip out" when the Centers for Medicare & Medicaid Services shuts down the price comparison website for drug discount cards in January 2006, former Centers for Medicare & Medicaid Services administrator Tom Scully predicts
Congress will move to strike down the Medicare Rx law's "non-interference" provision in the next two years, former Senate Finance Committee health advisor Kathleen Means said at the Biotechnology Industry Organization's annual conference in San Francisco June 9